AI-driven platforms can unlock large insurance and biopharma markets

Conviction: 55% · Horizon: 5Y · 2026-06-19
Selected AI-enabled companies may be underestimated relative to the size of their addressable markets

Large addressable markets in insurance and biopharma create room for scalable platforms to compound if they can convert technological differentiation into durable revenue growth.

Instrument Side Target Reason
LMND Long A digital insurer with improving automation and data advantages could capture meaningful share in a very large insurance market if underwriting quality and unit economics continue to improve.
LLY Long A scaled biopharma leader with strong innovation capacity can compound value if its pipeline and commercial execution keep expanding across large therapeutic markets.
ABCL Long An AI-enabled antibody discovery platform could generate outsized upside if partnerships and internal programs validate faster, more scalable biologics development.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.